CRISPR technology a silver lining in combating COVID-19 pandemic
The Applied Biology & Chemistry Journal · 2021
DOI: 10.52679/tabcj.2021.0004 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Applied Biology & Chemistry Journal, 2021. Verfasst von Ritesh Kumar Shukla und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Technological advancements have trigged the research arena of life sciences. This has resulted not only in the co-evolution of science and technology but also in building up novel ways to tackle life threatening pandemic like situations. The use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology in combating the recent COVID-19 pandemic is evidence to this. The technique was originally identified as a microbial adaptive immune system, in which the microbes use RNA-guided nucleases to cleave foreign genetic material. Subsequently, molecular biologists started harvesting this technique in accelerating the genetic engineering/ chimeric DNA methods. During COVID-19 outbreak, the scientists are trying to mould the CRISPR technology in the successful and rapid detection of the virus and also in the treatment of COVID- 19 infection. Thus the application of this technique comes as a ray of hope not only for fighting against COVID but also can be used as weapon for unseen future pandemics.
Zitieren
APA
Shukla, R. K., & Rao, N. V. A. (2021). CRISPR technology a silver lining in combating COVID-19 pandemic. The Applied Biology & Chemistry Journal. https://doi.org/10.52679/tabcj.2021.0004
Vancouver
Shukla RK, Rao NVA. CRISPR technology a silver lining in combating COVID-19 pandemic. The Applied Biology & Chemistry Journal. 2021. doi:10.52679/tabcj.2021.0004
BibTeX
@article{Shukla2021,
author = {Shukla, Ritesh Kumar and Rao, N Venkat Appa},
title = {CRISPR technology a silver lining in combating COVID-19 pandemic},
journal = {The Applied Biology & Chemistry Journal},
year = {2021},
doi = {10.52679/tabcj.2021.0004}
}
EUVIMED